NCT02520141View on ClinicalTrials.gov

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

June 29, 2022

Study Completion Date

June 29, 2022

Conditions
CholangiocarcinomaLiver and Intrahepatic Bile Duct CarcinomaStage III Gallbladder Cancer AJCC v7Stage III Intrahepatic Cholangiocarcinoma AJCC v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IV Gallbladder Cancer AJCC v7Stage IVA Gallbladder Cancer AJCC v7Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7Stage IVB Gallbladder Cancer AJCC v7Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7Unresectable Gallbladder Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Ramucirumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02520141 - Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter